Immunomodulation as innovative therapy for head and neck tumors. Current developments

被引：1
|
作者：
Schuler, P. J. [1 ]
Doescher, J. C. [1 ]
Laban, S. [1 ]
Hoffmann, T. K. [1 ]
机构：
[1] Univ Ulm Klinikum, Univ Klin Hals Nasen Ohrenheilkunde Kopf & Halsch, Frauensteige 12, D-89075 Ulm, Germany
来源：
HNO | 2016年 / 64卷 / 07期
关键词：
Head and neck neoplasms; Immunotherapy; Monoclonal antibodies; Programmed cell death 1 receptor; Vaccination; SQUAMOUS-CELL CARCINOMA; RECEPTOR FUSION PROTEIN; PHASE-I TRIAL; OPEN-LABEL; CANCER; RECURRENT; IMMUNOTHERAPY; DALANTERCEPT; COMBINATION; VACCINATION;
D O I：
10.1007/s00106-016-0131-0
中图分类号：
R76 [耳鼻咽喉科学];
学科分类号：
100213 ;
摘要：
Head and neck squamous cell carcinoma (HNSCC) is characterized by its intense immune suppression and its elaborate immune escape mechanisms. Due to the fact that survival rates remain low, the role of immunotherapy has become more important and the focus of current clinical studies has shifted toward antibody-based immune checkpoint modulation. Application of immunotherapy in curative settings or for prevention of recurrent disease would be desirable.
引用
收藏
页码：470 / 478
页数：9
相关论文
共 50 条
  • [31] Quality of life after treatment of head and neck tumors. Longitudinal comparison after operation and adjuvant radio(chemo)therapy
    Buecheler, B. M.
    Ehnes, A.
    Kavsadze, M.
    Langenberg, S.
    Wilhelm-Buchstab, T.
    Zipfel, M.
    Keiner, S.
    Gerstner, A. O. H.
    HNO, 2012, 60 (12) : 1053 - 1059
  • [32] Dermatologic Toxicities of Targeted Therapy and Immunotherapy in Head and Neck Cancers
    Espinosa, Maria L.
    Abad, Chelsea
    Kurtzman, Yaira
    Abdulla, Farah R.
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [33] Establishment of an immune-related gene prognostic model for head and neck tumors
    Zhou, F.
    Chen, A. X.
    Lv, H. Y.
    Liang, D. H.
    Yu, H. S.
    JOURNAL OF BIOLOGICAL REGULATORS AND HOMEOSTATIC AGENTS, 2021, 35 (03) : 975 - 986
  • [34] Current Status and Future Aspects of Stereotactic Body Radiotherapy and Immunotherapy in the Management of Recurrent Head and Neck Cancer
    Ozyigit, Gokhan
    Sari, Sezin Yuce
    Yazici, Gozde
    Cengiz, Mustafa
    TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY, 2019, 34 (04): : 313 - 320
  • [35] Immune checkpoint inhibitor use in head and neck squamous cell carcinoma: the current landscape and future perspectives
    Gatfield, Elinor R.
    Tadross, John
    Ince, William
    FUTURE ONCOLOGY, 2024, 20 (23) : 1695 - 1711
  • [36] Current Role of Dacomitinib in Head and Neck Cancer
    Elicin, Olgun
    Ozsahin, Mahmut
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2016, 25 (06) : 735 - 742
  • [37] New developments in the management of head and neck cancer - impact of pembrolizumab
    Saleh, Khalil
    Eid, Roland
    Haddad, Fady G. H.
    Khalife-Saleh, Nadine
    Kourie, Hampig Raphael
    THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2018, 14 : 295 - 303
  • [38] Essential news of current guidelines: head and neck squamous cell carcinoma
    Fuereder, Thorsten
    MEMO-MAGAZINE OF EUROPEAN MEDICAL ONCOLOGY, 2022, 15 (04) : 278 - 281
  • [39] Improving head and neck cancer therapies by immunomodulation of the tumour microenvironment
    Ruffin, Ayana T.
    Li, Housaiyin
    Vujanovic, Lazar
    Zandberg, Dan P.
    Ferris, Robert L.
    Bruno, Tullia C.
    NATURE REVIEWS CANCER, 2023, 23 (03) : 173 - 188
  • [40] Recurrent head and neck tumors after primary treatment
    Gauler, T.
    Gruenwald, V.
    ONKOLOGE, 2014, 20 (02): : 152 - 158
12345